statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

U.S. stocks were mixed, with the Dow Jones index falling over 50 points on Thursday.
Shares of Enliven Therapeutics, Inc. (NASDAQ: ELVN) rose sharply during Thursday's session.
read more...

Enliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On Thursday

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) Director Rahul D. Ballal sold 3,237 shares of Enliven Therapeutics stock in a transaction that occurred on Monday, April 1st. The shares...

Insider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) Director Sells $61,761.96 in Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) Director Rahul D. Ballal sold 3,237 shares of the business's stock in a transaction that occurred on Monday, April 1st. The stock was sold...

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Director Rahul D. Ballal Sells 3,237 Shares of Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) CFO Benjamin Hohl sold 3,250 shares of the firm's stock in a transaction on Wednesday, March 27th. The shares were sold at an average price...

Insider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Sells $59,312.50 in Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) CFO Benjamin Hohl sold 3,250 shares of the company's stock in a transaction on Wednesday, March 27th. The shares were sold at an average...

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl Sells 3,250 Shares of Stock

BOULDER, Colo., March 28, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and...

Enliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 2024

Enliven Therapeutics, Inc. (NASDAQ:ELVN  Get Free Report)s stock price dropped 3% on Thursday after an insider sold shares in the company. The company traded as low as $17.90 and last...

Enliven Therapeutics (NASDAQ:ELVN) Trading Down 3% After Insider Selling

Enliven Therapeutics, Inc. (NASDAQ:ELVN  Get Free Report) Director Richard A. Heyman sold 1,270 shares of the firms stock in a transaction dated Tuesday, March 19th. The shares were...

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Director Sells $18,415.00 in Stock

Enliven Therapeutics Inc Director Rahul Ballal Sells 13,278 Shares

This is a signal that ELVN's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...

Enliven Therapeutics (ELVN, $18) RSI Indicator left the overbought zone on March 21, 2024

Enliven Therapeutics, Inc. operates as a clinical stage precision oncology company. It is focused on the discovery and development of next-generation small molecule kinase inhibitors and advancing Enliven's pipeline of precision oncology product candidates. The company was founded by Sam S. Kintz, Joe P. Lyssikatos, and Anish Patel in June 2019 and is headquartered in Boulder, CO.

Volume	148,934.00
52-Wk High	$26.00
52-Wk Low	$9.80

ELVN Enliven Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals